The study involved nearly 1,300 adults with type 2 diabetes whose disease was inadequately controlled by metformin and other medications. Participants were divided into three groups: two received retatrutide at doses of 9 or 12 mg once weekly, and the third received ozempic at a dose of 2 mg. The average baseline HbA1c level was 8.3%, and participants weighed approximately 102 kg.
After 80 weeks, glycated hemoglobin levels decreased by an average of 2.2% in both retatrutide groups. In the ozempic group, the level decreased by 1.8%.
Weight loss with retartrutide ranged from 20 to 20.5 kg depending on the dosage. In the ozempic group, the average weight loss reached 9.5 kg. Retartrutide also provided more significant improvements in several cardiovascular risk indicators, including non-HDL cholesterol, triglycerides, and systolic blood pressure.
Retatrutide simultaneously targets three types of receptors involved in metabolic regulation: GIP, GLP-1, and glucagon. While retatrutide is currently in clinical trials, Eli Lilly is already preparing for regulatory approval. The company is confident that its market launch will change the paradigm for treating diabetes and obesity.
In another previous study, retatrutide helped people with type 2 diabetes and obesity lose approximately 23% of their body weight—an average of 27 kg. This is the highest weight loss ever recorded for an AGLP-1 inhibitor in people with diabetes.
